Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade) (NASDAQ:CLDX)

Group 1 - Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares have increased over 70% from their 60-month low in April 2025, which was attributed to high discontinuation rates for their lead asset, barzolvolimab [2] - The company is involved in mast cell therapy and has faced challenges with its primary asset, impacting its stock performance [2] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live discussions and weekly updates [2]